Showing 2001-2010 of 9112 results for "".
Why Lutronic
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/why-lutronic/19188/Established in 1997 by a group of accomplished scientists and prominent members of the medical community, LUTRONIC is passionate about improving the lives of physicians and their patients by developing solutions that are intuitive, versatile, and efficacious. Our customers choose our systems becauseRe-Considering the Psychological Components of Psoriasis
https://practicaldermatology.com/topics/psoriasis/re-considering-the-psychological-components-of-psoriasis/22962/With convincing data that show that psoriasis directly inhibits patients' daily activities and quality of life, clinicians must emphasize trust and empathy.Devices in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/devices-in-dermatology/22955/The State of the ArtQuestions on Established Patients, Medicare Services for Families, and Coding for Destructions
https://practicaldermatology.com/topics/practice-management/questions-on-established-patients-medicare-services-for-families-and-coding-for-destructions/21667/Seeing new patients doesn't necessarily provide better reimbursement than Established Patients. Here are answers to questions on this and other coding matters.Take 5: Promising Developments in Vitiligo Research
https://practicaldermatology.com/columns/take-5/promising-developments-in-vitiligo-research/21924/New studies suggest therapeutic pearls for the management of vitiligo and highlight new approaches to understanding the disorder.Take 5: Summer Skin Care Pearls to Share with Patients
https://practicaldermatology.com/columns/take-5/take-5-summer-skin-care-pearls-to-share-with-patients/21984/As summer approaches, here are five points you could mention to your patients about UV protection.Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.Who Is the Man at the Back?
https://practicaldermatology.com/issues/novemberdecember-2025/who-is-the-man-at-the-back/48887/The addiction to applause can often cloud the view of our surroundings and disconnect us from those who are not our allies.First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.Clinical Data on Switching to Upadacitinib
https://practicaldermatology.com/series/updates-atopic-dermatitis/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.